These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 24701734)

  • 21. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma.
    Pinilla I; Gómez-León N; Del Campo-Del Val L; Hernandez-Maraver D; Rodríguez-Vigil B; Jover-Díaz R; Coya J
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):567-75. PubMed ID: 21150860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
    Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET-CT.
    Kaltenbach TE; Graeter T; Mason RA; Kratzer W; Oeztuerk S; Haenle MM; Gruener B; Gottstein M
    Nuklearmedizin; 2015; 54(1):43-9. PubMed ID: 25423884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can 18F-FDG PET improve the evaluation of suspicious breast lesions on MRI?
    Bitencourt AG; Lima EN; Chojniak R; Marques EF; Souza JA; Andrade WP; Guimarães MD
    Eur J Radiol; 2014 Aug; 83(8):1381-6. PubMed ID: 24931922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
    García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
    Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
    Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
    Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
    Tirumani SH; LaCasce AS; Jacene HA
    PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
    Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L
    Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the International Harmonization Project, London and Gallamini criteria in the interpretation of 18F-FDG PET/CT examinations after first-line treatment in Hodgkin's lymphoma.
    Kajáry K; Molnár Z; Györke T; Szakáll S; Molnár P; Lengyel Z
    Nucl Med Commun; 2014 Feb; 35(2):169-75. PubMed ID: 24352108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.